$NHHS
NorthStar Healthcare Income, Inc.

2023 Q2 Form 10-Q Financial Statement

#000150370723000018 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $51.50M $49.57M $43.33M
YoY Change 13.51% 14.39% -24.42%
Cost Of Revenue $35.03M $35.08M $32.89M
YoY Change 5.4% 6.64% -27.89%
Gross Profit $16.48M $14.49M $10.44M
YoY Change 35.68% 38.83% -10.91%
Gross Profit Margin 31.99% 29.23% 24.09%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.808M $9.649M $9.923M
YoY Change 2.81% -2.76% -35.51%
% of Gross Profit 59.53% 66.59% 95.07%
Operating Expenses
YoY Change
Operating Profit
YoY Change
Interest Expense $11.53M $11.36M $10.31M
YoY Change 9.29% 10.19% -35.67%
% of Operating Profit
Other Income/Expense, Net $70.00K $132.0K $72.00K
YoY Change 1300.0% 83.33% -99.02%
Pretax Income -$56.46M -$10.06M -$15.47M
YoY Change 105.96% -34.96% 67.22%
Income Tax $11.00K $15.00K $15.00K
% Of Pretax Income
Net Earnings -$59.01M -$14.00M -$12.98M
YoY Change -990.51% 7.83% 27.83%
Net Earnings / Revenue -114.58% -28.24% -29.96%
Basic Earnings Per Share -$0.30 -$0.07 -$0.07
Diluted Earnings Per Share -$0.30 -$0.07 -$0.07
COMMON SHARES
Basic Shares Outstanding 195.4M shares 195.4M shares 193.4M shares
Diluted Shares Outstanding 193.2M shares 195.4M shares 193.4M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $107.3M $95.57M $191.2M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $2.085M $2.169M $2.506M
YoY Change -13.88% -13.45%
Long-Term Investments $128.2M $171.5M $207.4M
YoY Change -38.4% -17.33% -6.54%
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets $1.146B $1.218B $1.391B
YoY Change -11.23% -12.43% -26.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities $927.3M $929.6M $954.8M
YoY Change -1.85% -2.64% -35.42%
SHAREHOLDERS EQUITY
Retained Earnings -$1.501B -$1.443B -$1.291B
YoY Change 8.67% 11.79% -1.72%
Common Stock $1.718B $1.732B $1.725B
YoY Change -0.57% 0.36% 0.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $217.6M $286.3M $433.7M
YoY Change
Total Liabilities & Shareholders Equity $1.146B $1.218B $1.391B
YoY Change -11.23% -12.43% -26.11%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$59.01M -$14.00M -$12.98M
YoY Change -990.51% 7.83% 27.83%
Depreciation, Depletion And Amortization $9.808M $9.649M $9.923M
YoY Change 2.81% -2.76% -35.51%
Cash From Operating Activities -$3.536M -$10.84M
YoY Change -67.39% 62.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$523.0K $0.00
YoY Change
Cash From Investing Activities -$818.0K $4.716M
YoY Change -117.35% -89.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$4.828M -$4.297M
YoY Change 12.36% -78.88%
NET CHANGE
Cash From Operating Activities -$3.536M -$10.84M
Cash From Investing Activities -$818.0K $4.716M
Cash From Financing Activities -$4.828M -$4.297M
Net Change In Cash -$9.182M -$10.42M
YoY Change -11.91% -158.99%
FREE CASH FLOW
Cash From Operating Activities -$3.536M -$10.84M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503707
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#RealEstateInvestmentPropertyNet
CY2023Q1 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilities
CY2023Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#GainLossOnInvestments
CY2022Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2022#GainLossOnInvestments
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
000-55190
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NORTHSTAR HEALTHCARE INCOME, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MD
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3663988
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
16 East 34th Street
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
18th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
CY2023Q1 dei City Area Code
CityAreaCode
929
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
777-3135
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.01 per share
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
195421656 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95566000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103926000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
10912000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
11734000 usd
CY2023Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
928344000 usd
CY2022Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
933002000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
171495000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
176502000 usd
CY2023Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
2061000 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2815000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2169000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2253000 usd
CY2023Q1 us-gaap Other Assets
OtherAssets
7373000 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
7603000 usd
CY2023Q1 us-gaap Assets
Assets
1217920000 usd
CY2022Q4 us-gaap Assets
Assets
1237835000 usd
CY2023Q1 us-gaap Notes Payable
NotesPayable
908408000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
912248000 usd
CY2023Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
261000 usd
CY2022Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
469000 usd
CY2023Q1 us-gaap Advance Payments By Borrowers For Taxes And Insurance
AdvancePaymentsByBorrowersForTaxesAndInsurance
1323000 usd
CY2022Q4 us-gaap Advance Payments By Borrowers For Taxes And Insurance
AdvancePaymentsByBorrowersForTaxesAndInsurance
993000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
17720000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
21034000 usd
CY2023Q1 us-gaap Other Liabilities
OtherLiabilities
1862000 usd
CY2022Q4 us-gaap Other Liabilities
OtherLiabilities
2019000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
929574000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
936763000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195421656 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
195421656 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
195421656 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
195421656 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1954000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1954000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1729589000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1729589000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1442766000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1428840000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2431000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3679000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
286346000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
299024000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
2000000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
2048000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288346000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
301072000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1217920000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1237835000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11850000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10755000 usd
CY2023Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
36999000 usd
CY2022Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
32559000 usd
CY2023Q1 us-gaap Other Operating Income
OtherOperatingIncome
719000 usd
CY2022Q1 us-gaap Other Operating Income
OtherOperatingIncome
18000 usd
CY2023Q1 us-gaap Revenues
Revenues
49568000 usd
CY2022Q1 us-gaap Revenues
Revenues
43332000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35077000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32894000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
11359000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
10309000 usd
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
97000 usd
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 usd
CY2023Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0 usd
CY2022Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2647000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3910000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3686000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9649000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
60092000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
59459000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
132000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
332000 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10060000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15468000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3922000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13997000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-71000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-45000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13926000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13926000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12936000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12936000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
195421656 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
195421656 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
193368486 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
193368486 shares
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
49872 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
66840 shares
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13997000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1248000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-568000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1248000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-568000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-12749000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13549000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-71000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-45000 usd
CY2023Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.069
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12678000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13504000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
446818000 usd
CY2022Q1 nshi Stock Redeemedor Called During Period Value Paymentof Advisor Asset Management Fees
StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees
2729000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15000 usd
CY2022Q1 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
64000 usd
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
53000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-568000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
436024000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
301072000 usd
CY2023Q1 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
45000 usd
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
22000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1248000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13997000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
288346000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13997000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3922000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9649000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 usd
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
824000 usd
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
804000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
155000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
154000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
57000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
48000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
332000 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
167000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
58000 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2647000 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-587000 usd
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1502000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
374000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1665000 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-208000 usd
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-3115000 usd
CY2023Q1 nshi Increase Decreasein Escrow Payable
IncreaseDecreaseinEscrowPayable
330000 usd
CY2022Q1 nshi Increase Decreasein Escrow Payable
IncreaseDecreaseinEscrowPayable
295000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4445000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5751000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
129000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
327000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3536000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10843000 usd
CY2023Q1 nshi Paymentsto Improve Real Estate
PaymentstoImproveRealEstate
3810000 usd
CY2022Q1 nshi Paymentsto Improve Real Estate
PaymentstoImproveRealEstate
2337000 usd
CY2023Q1 nshi Proceeds From Sale Of Real Estate Investing
ProceedsFromSaleOfRealEstateInvesting
135000 usd
CY2022Q1 nshi Proceeds From Sale Of Real Estate Investing
ProceedsFromSaleOfRealEstateInvesting
0 usd
CY2023Q1 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
2334000 usd
CY2022Q1 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
7053000 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-523000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-818000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4716000 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4819000 usd
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4171000 usd
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
32000 usd
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
137000 usd
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
45000 usd
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
64000 usd
CY2023Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
22000 usd
CY2022Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
53000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4828000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4297000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9182000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10424000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115660000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
210938000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106478000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200514000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
10434000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
9121000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1071000 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
364000 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
Business and Organization<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), owns a diversified portfolio of seniors housing properties, including independent living facilities (“ILF”), assisted living (“ALF”) and memory care facilities (“MCF”) located throughout the United States. In addition, the Company also has made investments through non-controlling interests in joint ventures in a broader spectrum of healthcare real estate, including seniors housing properties, as well as continuing care retirement communities (“CCRC”), skilled nursing (“SNF”), medical office buildings (“MOB”), specialty hospitals and ancillary services businesses, across the United States and United Kingdom.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company has conducted its operations, and intends to do so in the future, so as to continue to qualify as a REIT for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”). NorthStar Healthcare Income Advisor, LLC invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which are collectively recorded as non-controlling interests on the accompanying consolidated balance sheets as of March 31, 2023 and December 31, 2022. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of March 31, 2023, the Company’s limited partnership interest in the Operating Partnership was 99.99%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company raised $2.0 billion in total gross proceeds from the sale of shares of common stock in its continuous, public offerings (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”). </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Internalization</span></div>From inception through October 21, 2022, the Company was externally managed by CNI NSHC Advisors, LLC or its predecessor (the “Former Advisor”), an affiliate of NRF Holdco, LLC (the “Former Sponsor”). The Former Advisor was responsible for managing the Company’s operations, subject to the supervision of the Company’s board of directors, pursuant to an advisory agreement. On October 21, 2022, the Company completed the internalization of the Company’s management function (the “Internalization”). In connection with the Internalization, the Company agreed with the Former Advisor to terminate the advisory agreement and arranged for the Former Advisor to continue to provide certain services for a transition period.
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000000000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
171500000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
244000 usd
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
35000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.</span></div>
CY2023Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95566000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103926000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
10912000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
11734000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106478000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115660000 usd
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
209000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
500000 usd
CY2023Q1 nshi Finance Lease Payments
FinanceLeasePayments
29070000 usd
CY2022Q1 nshi Finance Lease Payments
FinanceLeasePayments
138942000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
76000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
69000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
38000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
33000 usd
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
18000 usd
CY2023Q1 nshi Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
10000 usd
CY2023Q1 nshi Number Of Triple Net Lease Portfolios
NumberOfTripleNetLeasePortfolios
4 portfolio
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
117980000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
117896000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2169000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2253000 usd
CY2023Q1 nshi Amortizationof Deferred Costsand Intangible Assets
AmortizationofDeferredCostsandIntangibleAssets
100000 usd
CY2022Q1 nshi Amortizationof Deferred Costsand Intangible Assets
AmortizationofDeferredCostsandIntangibleAssets
100000 usd
CY2023Q1 nshi Deferred Costsand Finite Lived Intangible Assets Amortization Expense Remainderof Fiscal Year
DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear
253000 usd
CY2023Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year One
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearOne
337000 usd
CY2023Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Two
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
337000 usd
CY2023Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Three
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearThree
337000 usd
CY2023Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Four
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearFour
337000 usd
CY2023Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense After Year Four
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
568000 usd
CY2023Q1 nshi Deferred Costsand Finite Lived Intangible Assets Net
DeferredCostsandFiniteLivedIntangibleAssetsNet
2169000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-200000 usd
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
300000 usd
CY2023Q1 nshi Lease Terms Days Notice Required For Termination
LeaseTermsDaysNoticeRequiredForTermination
30 d
CY2023Q1 nshi Lease Terms Days Notice Required For Termination
LeaseTermsDaysNoticeRequiredForTermination
30 d
CY2023Q1 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
3400000 usd
CY2022Q1 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
1600000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q1 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15400000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2023Q1 us-gaap Land
Land
121518000 usd
CY2022Q4 us-gaap Land
Land
121518000 usd
CY2023Q1 us-gaap Land Improvements
LandImprovements
19063000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
9800000 usd
CY2022Q4 us-gaap Land Improvements
LandImprovements
18945000 usd
CY2023Q1 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
962877000 usd
CY2022Q4 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
957924000 usd
CY2023Q1 us-gaap Tenant Improvements
TenantImprovements
372000 usd
CY2022Q4 us-gaap Tenant Improvements
TenantImprovements
372000 usd
CY2023Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
4911000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6736000 usd
CY2023Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
92656000 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
91058000 usd
CY2023Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
1201397000 usd
CY2022Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
1196553000 usd
CY2023Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
273053000 usd
CY2022Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
263551000 usd
CY2023Q1 us-gaap Real Estate Investments
RealEstateInvestments
928344000 usd
CY2022Q4 us-gaap Real Estate Investments
RealEstateInvestments
933002000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
9600000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
171495000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
176502000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3922000 usd
CY2023Q1 nshi Proceeds From Equity Method Investment Distribution Operating And Investing Activities
ProceedsFromEquityMethodInvestmentDistributionOperatingAndInvestingActivities
2334000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 usd
CY2022Q1 nshi Proceeds From Equity Method Investment Distribution Operating And Investing Activities
ProceedsFromEquityMethodInvestmentDistributionOperatingAndInvestingActivities
7053000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
25434000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
19612000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
669466000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
46876000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
156145000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
917533000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56875 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47500 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
154375 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
211250 usd
CY2022Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.50
CY2022Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
97000000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
226500000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-71242 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-45468 usd
CY2022 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1000000 usd
CY2023Q1 nshi Rentaland Resident Fee Income
RentalandResidentFeeIncome
49568000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35077000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
11359000 usd
CY2023Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
97000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3910000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9649000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
132000 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
332000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3922000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13997000 usd
CY2022Q1 nshi Rentaland Resident Fee Income
RentalandResidentFeeIncome
43332000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32894000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
10309000 usd
CY2022Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2647000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3686000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 usd
CY2023Q1 us-gaap Assets
Assets
1217920000 usd
CY2022Q4 us-gaap Assets
Assets
1237835000 usd
CY2023Q1 us-gaap Number Of Real Estate Properties
NumberOfRealEstateProperties
56 property
CY2023Q1 us-gaap Number Of Units In Real Estate Property
NumberOfUnitsInRealEstateProperty
6840 unit
CY2023Q1 us-gaap Noninterest Income
NoninterestIncome
49568000 usd
CY2023Q1 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
500000 usd

Files In Submission

Name View Source Status
nshi-20230331_lab.xml Edgar Link unprocessable
nshi-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
nshi-20230331_cal.xml Edgar Link unprocessable
0001503707-23-000018-index-headers.html Edgar Link pending
0001503707-23-000018-index.html Edgar Link pending
0001503707-23-000018.txt Edgar Link pending
0001503707-23-000018-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nshi-20230331.htm Edgar Link pending
nshi-20230331.xsd Edgar Link pending
nshi-20230331_g1.jpg Edgar Link pending
nshi-20230331_g2.jpg Edgar Link pending
nshi03312023exhibit311.htm Edgar Link pending
nshi03312023exhibit312.htm Edgar Link pending
nshi03312023exhibit321.htm Edgar Link pending
nshi03312023exhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
nshi-20230331_pre.xml Edgar Link unprocessable
nshi-20230331_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending